SCHEMBL2575436

SCHEMBL2575436

O=C(NC1CCCC1)Oc1cnc(-n2cccn2)nc1O

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.42
EPHX1 P07099 2/20 0.40
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 1/20 0.39
FAAH O00519 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
TSHR P16473 1/20 0.37
CD38 P28907 3/20 0.36
LHCGR P22888 1/20 0.36
CHRM1 P11229 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2575729 0.99 EPHX1 (0.41) ADORA2AEPHX1ALDH1A1RAB9AFAAH
SCHEMBL2564593 0.79 KMT2A (0.44) ADORA2AEPHX1ALDH1A1RAB9ATSHR
SCHEMBL2564810 0.79 EGLN1 (0.36) ADORA2AALDH1A1EGLN1
SCHEMBL2566363 0.78 KMT2A (0.46) EPHX1ALDH1A1RAB9ATSHR
SCHEMBL2566114 0.78 HPGD (0.41) ADORA2AALDH1A1RAB9ATSHRCD38
SCHEMBL2575235 0.78 HSP90AA1 (0.46) ALDH1A1RAB9AFAAHEGLN1TSHR
SCHEMBL16005608 0.76 EGLN1 (0.37) ADORA2AALDH1A1EGLN1
SCHEMBL2573169 0.75 NCEH1 (0.41)
SCHEMBL14575605 0.74 BCL6 (0.35) ADORA2AEGLN1
SCHEMBL2560122 0.74 PORCN (0.42) ALDH1A1FAAHEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560655-B1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME (US) 2016-08-24 EP claimed
US-9006433-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-04-14 US claimed
EP-2560655-A1 SUBSTITUTED PYRIMIDINES Merck Sharp & Dohme Corp. (US) 2013-02-27 EP claimed
WO-2011130908-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO claimed
WO-2011133444-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO claimed
EP-2560655-B1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME (US) 2016-08-24 EP disclosed
EP-2560655-A1 SUBSTITUTED PYRIMIDINES Merck Sharp & Dohme Corp. (US) 2013-02-27 EP disclosed
US-20130018053-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME LLC 2013-01-17 US disclosed
WO-2011130908-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO disclosed
WO-2011133444-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018053-A1 SUBSTITUTED PYRIMIDINES HIF1AN, HIF1A, EGLN3 ADORA2A 874/4885EPHX1 621/4885ALDH1A1 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.